Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Afatinib for First-Line Treatment of EGFR Mutation-Positive Advanced NSCLC: The LUX-Lung 3 Trial
Author
Howard (Jack) West, MD

As part of our program on lung cancer highlights, Dr. Joel Neal covered the LUX-Lung 3 trial, a global study that randomized patients with advanced NSCLC and an EGFR mutation to either afatinib, an "irreversible pan-HER inhibitor" that could potentially be an advance over the current EGFR inhibitors we have available now, or standard chemotherapy with cisplatin/Alimta (pemetrexed).  It provided some interesting results, though the question is whether the performance of afatinib exceeded what we might expect from Tarceva (erlotinib) or Iressa (gefitinib), except in terms of side effects, which were more severe and more common with afatinib.  Still, it was a positive trial that I expect will lead to an FDA approval and the commercial availability of afatinib for this clinical population.

Here's Dr. Neal's coverage of the trial, in both video and audio podcast form, as well as the associated transcript and figures for the podcast.

Dr. Neal ASCO 2012 LC Highlights LUX-Lung 3 Audio Podcast

Dr. Neal ASCO 2012 LC Highlights LUX-Lung 3 Figs

Dr. Neal ASCO LC Highlights 2012 LUX-Lung 3 Transcript

In short order we'll have Dr. Neal's summary of the interesting trial of the MEK inhibitor selumetinib for KRAS mutation-positive patients available, too; in the meantime, what do you think of these results? Would you be inclined to favor afatinib now if you had an EGFR mutation, or would you favor Iressa or Tarceva instead? How much does your answer depend on the survival results for the afatinib?

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Imagine your body's defense system, the lymphatic system, suddenly turning against you. This is the reality for those facing lymphoma, a cancer of the immune system's crucial network. This article delves into the complexities of lymphoma, exploring its various forms, from the aggressive to the indolent, and examining the latest breakthroughs in treatment, including the groundbreaking POLARIX trial and cutting-edge therapies for relapsed cases. Whether you're a patient, a loved one, or simply curious about this complex disease, this comprehensive overview will provide valuable insights into the current state of lymphoma care and the promising future of research.
Image
Melanoma Video Library
Video
In these videos, Dr. Autumn Starnes gives an overview of melanoma's prevalence and risk factors. She also discusses the ABCDE method of self-screening for skin cancer, common misconceptions regarding people of color, and melanoma, and how a person can lower their risk of developing melanoma, among other relevant topics regarding melanoma.  To watch the complete playlist, click here. 

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Glad to help.  FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/

Hope to see...

Recent Comments

JOIN THE CONVERSATION
Glad to help.  FYI, I just…
By JanineT GRACE … on
I was searching for this,…
By LilahStapleton on
Hi and welcome.  I'm sorry…
By JanineT GRACE … on
Hi amitchouhan,

Welcome to…
By JanineT GRACE … on